Here is why Pfizer can't seem to get off the mat and whether it's worth buying the dip on today. I won't rehash Pfizer's pandemic journey too much. The company developed and sold a vaccine (Comirnaty) ...

Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2 drug at the ASCO Annual Meeting, and ...

Pfizer's (NYSE: PFE) management team is confident in its 2025 opportunities. Where to invest $1,000 right now? Our analyst ...

Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. Markets expect ...

Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded ...

Talzenna is currently approved in combination with Xtandi (enzalutamide) for individuals with castration-resistant prostate ...

The stock's fall snapped a four-day winning streak.

Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss t ...

Detailed price information for Coca-Cola Company (KO-N) from The Globe and Mail including charting and trades.